Inactive Instrument

News Zalicus Inc Nasdaq

Equities

US98887C1053

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2018	Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	CI
2018	Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	18-10-09	CI
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	18-01-30	CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	18-01-19	CI
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.	18-01-17	CI
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.	17-12-11	CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	16-09-19	CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index	16-08-05	CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index	16-08-03	CI
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations	16-07-25	CI
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy	16-07-25	CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination	16-07-01	CI
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..	16-06-29	CI
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.	16-06-13	CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes	16-05-09	CI
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	16-03-28	CI
Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016	16-03-15
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	16-03-15	CI
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)	16-02-09	CI
Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015	15-11-16
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015	15-11-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zalicus Inc Nasdaq

Equities

US98887C1053

Summary

Filters